nodes	percent_of_prediction	percent_of_DWPC	metapath
Raltegravir—CCR1—myometrium—ovarian cancer	0.0441	0.178	CbGeAlD
Raltegravir—CCR1—decidua—ovarian cancer	0.0327	0.132	CbGeAlD
Raltegravir—CCR1—endometrium—ovarian cancer	0.031	0.125	CbGeAlD
Raltegravir—CCR1—uterus—ovarian cancer	0.0286	0.115	CbGeAlD
Raltegravir—CCR1—female reproductive system—ovarian cancer	0.0257	0.104	CbGeAlD
Raltegravir—CCR1—bone marrow—ovarian cancer	0.0243	0.0978	CbGeAlD
Raltegravir—CCR1—female gonad—ovarian cancer	0.0234	0.0943	CbGeAlD
Raltegravir—CCR1—vagina—ovarian cancer	0.0232	0.0937	CbGeAlD
Raltegravir—CCR1—lymph node—ovarian cancer	0.015	0.0606	CbGeAlD
Raltegravir—Infection—Paclitaxel—ovarian cancer	0.000582	0.000774	CcSEcCtD
Raltegravir—Dry skin—Doxorubicin—ovarian cancer	0.000578	0.000768	CcSEcCtD
Raltegravir—Dizziness—Vinorelbine—ovarian cancer	0.000576	0.000766	CcSEcCtD
Raltegravir—Abdominal pain upper—Doxorubicin—ovarian cancer	0.000576	0.000765	CcSEcCtD
Raltegravir—Nervous system disorder—Paclitaxel—ovarian cancer	0.000574	0.000764	CcSEcCtD
Raltegravir—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000573	0.000762	CcSEcCtD
Raltegravir—Breast disorder—Doxorubicin—ovarian cancer	0.00057	0.000757	CcSEcCtD
Raltegravir—Skin disorder—Paclitaxel—ovarian cancer	0.000569	0.000756	CcSEcCtD
Raltegravir—Aspartate aminotransferase increased—Doxorubicin—ovarian cancer	0.000568	0.000755	CcSEcCtD
Raltegravir—Bronchitis—Epirubicin—ovarian cancer	0.000566	0.000753	CcSEcCtD
Raltegravir—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000566	0.000753	CcSEcCtD
Raltegravir—Nasopharyngitis—Doxorubicin—ovarian cancer	0.000564	0.000749	CcSEcCtD
Raltegravir—Anaemia—Docetaxel—ovarian cancer	0.000562	0.000747	CcSEcCtD
Raltegravir—Gastritis—Doxorubicin—ovarian cancer	0.000558	0.000742	CcSEcCtD
Raltegravir—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	0.000556	0.000739	CcSEcCtD
Raltegravir—Vomiting—Vinorelbine—ovarian cancer	0.000554	0.000736	CcSEcCtD
Raltegravir—Neutropenia—Epirubicin—ovarian cancer	0.000551	0.000732	CcSEcCtD
Raltegravir—Rash—Vinorelbine—ovarian cancer	0.000549	0.00073	CcSEcCtD
Raltegravir—Dermatitis—Vinorelbine—ovarian cancer	0.000548	0.000729	CcSEcCtD
Raltegravir—Abdominal distension—Doxorubicin—ovarian cancer	0.000548	0.000729	CcSEcCtD
Raltegravir—Upper respiratory tract infection—Epirubicin—ovarian cancer	0.000547	0.000728	CcSEcCtD
Raltegravir—Headache—Vinorelbine—ovarian cancer	0.000545	0.000725	CcSEcCtD
Raltegravir—Influenza—Doxorubicin—ovarian cancer	0.000545	0.000724	CcSEcCtD
Raltegravir—Eosinophilia—Doxorubicin—ovarian cancer	0.000539	0.000717	CcSEcCtD
Raltegravir—Palpitations—Docetaxel—ovarian cancer	0.000537	0.000715	CcSEcCtD
Raltegravir—Weight increased—Epirubicin—ovarian cancer	0.000536	0.000712	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000534	0.000709	CcSEcCtD
Raltegravir—Weight decreased—Epirubicin—ovarian cancer	0.000533	0.000708	CcSEcCtD
Raltegravir—Hyperglycaemia—Epirubicin—ovarian cancer	0.000531	0.000706	CcSEcCtD
Raltegravir—Cough—Docetaxel—ovarian cancer	0.000531	0.000706	CcSEcCtD
Raltegravir—Insomnia—Paclitaxel—ovarian cancer	0.00053	0.000704	CcSEcCtD
Raltegravir—Paraesthesia—Paclitaxel—ovarian cancer	0.000526	0.000699	CcSEcCtD
Raltegravir—Hypertension—Docetaxel—ovarian cancer	0.000525	0.000698	CcSEcCtD
Raltegravir—Infestation NOS—Epirubicin—ovarian cancer	0.000525	0.000698	CcSEcCtD
Raltegravir—Infestation—Epirubicin—ovarian cancer	0.000525	0.000698	CcSEcCtD
Raltegravir—Bronchitis—Doxorubicin—ovarian cancer	0.000524	0.000697	CcSEcCtD
Raltegravir—Somnolence—Paclitaxel—ovarian cancer	0.000521	0.000692	CcSEcCtD
Raltegravir—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	0.00052	0.000692	CcSEcCtD
Raltegravir—Arthralgia—Docetaxel—ovarian cancer	0.000518	0.000688	CcSEcCtD
Raltegravir—Chest pain—Docetaxel—ovarian cancer	0.000518	0.000688	CcSEcCtD
Raltegravir—Myalgia—Docetaxel—ovarian cancer	0.000518	0.000688	CcSEcCtD
Raltegravir—Nausea—Vinorelbine—ovarian cancer	0.000517	0.000688	CcSEcCtD
Raltegravir—Renal failure—Epirubicin—ovarian cancer	0.000516	0.000686	CcSEcCtD
Raltegravir—Dyspepsia—Paclitaxel—ovarian cancer	0.000516	0.000685	CcSEcCtD
Raltegravir—Neuropathy peripheral—Epirubicin—ovarian cancer	0.000515	0.000684	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000514	0.000684	CcSEcCtD
Raltegravir—Neutropenia—Doxorubicin—ovarian cancer	0.000509	0.000677	CcSEcCtD
Raltegravir—Decreased appetite—Paclitaxel—ovarian cancer	0.000509	0.000677	CcSEcCtD
Raltegravir—Dry mouth—Docetaxel—ovarian cancer	0.000506	0.000673	CcSEcCtD
Raltegravir—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000506	0.000673	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000506	0.000672	CcSEcCtD
Raltegravir—Fatigue—Paclitaxel—ovarian cancer	0.000505	0.000671	CcSEcCtD
Raltegravir—Pain—Paclitaxel—ovarian cancer	0.000501	0.000666	CcSEcCtD
Raltegravir—Constipation—Paclitaxel—ovarian cancer	0.000501	0.000666	CcSEcCtD
Raltegravir—Haematuria—Epirubicin—ovarian cancer	0.000501	0.000666	CcSEcCtD
Raltegravir—Confusional state—Docetaxel—ovarian cancer	0.000501	0.000665	CcSEcCtD
Raltegravir—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000496	0.00066	CcSEcCtD
Raltegravir—Weight increased—Doxorubicin—ovarian cancer	0.000496	0.000659	CcSEcCtD
Raltegravir—Epistaxis—Epirubicin—ovarian cancer	0.000495	0.000658	CcSEcCtD
Raltegravir—Infection—Docetaxel—ovarian cancer	0.000493	0.000656	CcSEcCtD
Raltegravir—Weight decreased—Doxorubicin—ovarian cancer	0.000493	0.000655	CcSEcCtD
Raltegravir—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000491	0.000653	CcSEcCtD
Raltegravir—Nervous system disorder—Docetaxel—ovarian cancer	0.000487	0.000647	CcSEcCtD
Raltegravir—Thrombocytopenia—Docetaxel—ovarian cancer	0.000486	0.000646	CcSEcCtD
Raltegravir—Infestation—Doxorubicin—ovarian cancer	0.000486	0.000646	CcSEcCtD
Raltegravir—Infestation NOS—Doxorubicin—ovarian cancer	0.000486	0.000646	CcSEcCtD
Raltegravir—Feeling abnormal—Paclitaxel—ovarian cancer	0.000483	0.000642	CcSEcCtD
Raltegravir—Skin disorder—Docetaxel—ovarian cancer	0.000482	0.000641	CcSEcCtD
Raltegravir—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.000482	0.00064	CcSEcCtD
Raltegravir—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000479	0.000637	CcSEcCtD
Raltegravir—Renal failure—Doxorubicin—ovarian cancer	0.000477	0.000635	CcSEcCtD
Raltegravir—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.000476	0.000633	CcSEcCtD
Raltegravir—Hepatitis—Epirubicin—ovarian cancer	0.000471	0.000627	CcSEcCtD
Raltegravir—Hypoaesthesia—Epirubicin—ovarian cancer	0.000469	0.000623	CcSEcCtD
Raltegravir—Urinary tract disorder—Epirubicin—ovarian cancer	0.000465	0.000619	CcSEcCtD
Raltegravir—Urticaria—Paclitaxel—ovarian cancer	0.000465	0.000619	CcSEcCtD
Raltegravir—Oedema peripheral—Epirubicin—ovarian cancer	0.000464	0.000617	CcSEcCtD
Raltegravir—Haematuria—Doxorubicin—ovarian cancer	0.000463	0.000616	CcSEcCtD
Raltegravir—Connective tissue disorder—Epirubicin—ovarian cancer	0.000463	0.000616	CcSEcCtD
Raltegravir—Abdominal pain—Paclitaxel—ovarian cancer	0.000463	0.000616	CcSEcCtD
Raltegravir—Body temperature increased—Paclitaxel—ovarian cancer	0.000463	0.000616	CcSEcCtD
Raltegravir—Urethral disorder—Epirubicin—ovarian cancer	0.000462	0.000614	CcSEcCtD
Raltegravir—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000459	0.000611	CcSEcCtD
Raltegravir—Epistaxis—Doxorubicin—ovarian cancer	0.000458	0.000609	CcSEcCtD
Raltegravir—Visual impairment—Epirubicin—ovarian cancer	0.000454	0.000604	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000452	0.000601	CcSEcCtD
Raltegravir—Insomnia—Docetaxel—ovarian cancer	0.000449	0.000597	CcSEcCtD
Raltegravir—Paraesthesia—Docetaxel—ovarian cancer	0.000446	0.000593	CcSEcCtD
Raltegravir—Erythema multiforme—Epirubicin—ovarian cancer	0.000446	0.000592	CcSEcCtD
Raltegravir—Somnolence—Docetaxel—ovarian cancer	0.000441	0.000587	CcSEcCtD
Raltegravir—Eye disorder—Epirubicin—ovarian cancer	0.00044	0.000586	CcSEcCtD
Raltegravir—Tinnitus—Epirubicin—ovarian cancer	0.000439	0.000584	CcSEcCtD
Raltegravir—Cardiac disorder—Epirubicin—ovarian cancer	0.000437	0.000582	CcSEcCtD
Raltegravir—Dyspepsia—Docetaxel—ovarian cancer	0.000437	0.000581	CcSEcCtD
Raltegravir—Hepatitis—Doxorubicin—ovarian cancer	0.000436	0.00058	CcSEcCtD
Raltegravir—Hypoaesthesia—Doxorubicin—ovarian cancer	0.000434	0.000577	CcSEcCtD
Raltegravir—Decreased appetite—Docetaxel—ovarian cancer	0.000432	0.000574	CcSEcCtD
Raltegravir—Hypersensitivity—Paclitaxel—ovarian cancer	0.000431	0.000574	CcSEcCtD
Raltegravir—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000431	0.000573	CcSEcCtD
Raltegravir—Oedema peripheral—Doxorubicin—ovarian cancer	0.00043	0.000571	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000429	0.00057	CcSEcCtD
Raltegravir—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000428	0.00057	CcSEcCtD
Raltegravir—Fatigue—Docetaxel—ovarian cancer	0.000428	0.000569	CcSEcCtD
Raltegravir—Angiopathy—Epirubicin—ovarian cancer	0.000428	0.000568	CcSEcCtD
Raltegravir—Urethral disorder—Doxorubicin—ovarian cancer	0.000427	0.000568	CcSEcCtD
Raltegravir—Immune system disorder—Epirubicin—ovarian cancer	0.000426	0.000566	CcSEcCtD
Raltegravir—Mediastinal disorder—Epirubicin—ovarian cancer	0.000425	0.000565	CcSEcCtD
Raltegravir—Constipation—Docetaxel—ovarian cancer	0.000424	0.000564	CcSEcCtD
Raltegravir—Pain—Docetaxel—ovarian cancer	0.000424	0.000564	CcSEcCtD
Raltegravir—Chills—Epirubicin—ovarian cancer	0.000423	0.000562	CcSEcCtD
Raltegravir—Visual impairment—Doxorubicin—ovarian cancer	0.00042	0.000559	CcSEcCtD
Raltegravir—Asthenia—Paclitaxel—ovarian cancer	0.00042	0.000559	CcSEcCtD
Raltegravir—Alopecia—Epirubicin—ovarian cancer	0.000416	0.000554	CcSEcCtD
Raltegravir—Pruritus—Paclitaxel—ovarian cancer	0.000414	0.000551	CcSEcCtD
Raltegravir—Mental disorder—Epirubicin—ovarian cancer	0.000413	0.000549	CcSEcCtD
Raltegravir—Erythema multiforme—Doxorubicin—ovarian cancer	0.000412	0.000548	CcSEcCtD
Raltegravir—Malnutrition—Epirubicin—ovarian cancer	0.00041	0.000545	CcSEcCtD
Raltegravir—Erythema—Epirubicin—ovarian cancer	0.00041	0.000545	CcSEcCtD
Raltegravir—Feeling abnormal—Docetaxel—ovarian cancer	0.000409	0.000544	CcSEcCtD
Raltegravir—Eye disorder—Doxorubicin—ovarian cancer	0.000408	0.000542	CcSEcCtD
Raltegravir—Tinnitus—Doxorubicin—ovarian cancer	0.000407	0.000541	CcSEcCtD
Raltegravir—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000406	0.00054	CcSEcCtD
Raltegravir—Cardiac disorder—Doxorubicin—ovarian cancer	0.000405	0.000538	CcSEcCtD
Raltegravir—Flatulence—Epirubicin—ovarian cancer	0.000404	0.000537	CcSEcCtD
Raltegravir—Dysgeusia—Epirubicin—ovarian cancer	0.000402	0.000534	CcSEcCtD
Raltegravir—Diarrhoea—Paclitaxel—ovarian cancer	0.000401	0.000533	CcSEcCtD
Raltegravir—Nervousness—Epirubicin—ovarian cancer	0.000398	0.00053	CcSEcCtD
Raltegravir—Back pain—Epirubicin—ovarian cancer	0.000397	0.000528	CcSEcCtD
Raltegravir—Angiopathy—Doxorubicin—ovarian cancer	0.000396	0.000526	CcSEcCtD
Raltegravir—Immune system disorder—Doxorubicin—ovarian cancer	0.000394	0.000524	CcSEcCtD
Raltegravir—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000393	0.000523	CcSEcCtD
Raltegravir—Abdominal pain—Docetaxel—ovarian cancer	0.000392	0.000522	CcSEcCtD
Raltegravir—Body temperature increased—Docetaxel—ovarian cancer	0.000392	0.000522	CcSEcCtD
Raltegravir—Chills—Doxorubicin—ovarian cancer	0.000391	0.00052	CcSEcCtD
Raltegravir—Dizziness—Paclitaxel—ovarian cancer	0.000387	0.000515	CcSEcCtD
Raltegravir—Alopecia—Doxorubicin—ovarian cancer	0.000385	0.000512	CcSEcCtD
Raltegravir—Mental disorder—Doxorubicin—ovarian cancer	0.000382	0.000508	CcSEcCtD
Raltegravir—Ill-defined disorder—Epirubicin—ovarian cancer	0.000381	0.000506	CcSEcCtD
Raltegravir—Erythema—Doxorubicin—ovarian cancer	0.00038	0.000505	CcSEcCtD
Raltegravir—Malnutrition—Doxorubicin—ovarian cancer	0.00038	0.000505	CcSEcCtD
Raltegravir—Anaemia—Epirubicin—ovarian cancer	0.000379	0.000504	CcSEcCtD
Raltegravir—Agitation—Epirubicin—ovarian cancer	0.000377	0.000501	CcSEcCtD
Raltegravir—Flatulence—Doxorubicin—ovarian cancer	0.000374	0.000497	CcSEcCtD
Raltegravir—Vomiting—Paclitaxel—ovarian cancer	0.000372	0.000495	CcSEcCtD
Raltegravir—Dysgeusia—Doxorubicin—ovarian cancer	0.000372	0.000494	CcSEcCtD
Raltegravir—Malaise—Epirubicin—ovarian cancer	0.00037	0.000492	CcSEcCtD
Raltegravir—Rash—Paclitaxel—ovarian cancer	0.000369	0.000491	CcSEcCtD
Raltegravir—Dermatitis—Paclitaxel—ovarian cancer	0.000369	0.000491	CcSEcCtD
Raltegravir—Nervousness—Doxorubicin—ovarian cancer	0.000369	0.00049	CcSEcCtD
Raltegravir—Vertigo—Epirubicin—ovarian cancer	0.000369	0.00049	CcSEcCtD
Raltegravir—Back pain—Doxorubicin—ovarian cancer	0.000367	0.000488	CcSEcCtD
Raltegravir—Headache—Paclitaxel—ovarian cancer	0.000367	0.000488	CcSEcCtD
Raltegravir—Hypersensitivity—Docetaxel—ovarian cancer	0.000366	0.000486	CcSEcCtD
Raltegravir—Palpitations—Epirubicin—ovarian cancer	0.000363	0.000482	CcSEcCtD
Raltegravir—Cough—Epirubicin—ovarian cancer	0.000358	0.000476	CcSEcCtD
Raltegravir—Asthenia—Docetaxel—ovarian cancer	0.000356	0.000474	CcSEcCtD
Raltegravir—Hypertension—Epirubicin—ovarian cancer	0.000354	0.000471	CcSEcCtD
Raltegravir—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000352	0.000468	CcSEcCtD
Raltegravir—Pruritus—Docetaxel—ovarian cancer	0.000351	0.000467	CcSEcCtD
Raltegravir—Anaemia—Doxorubicin—ovarian cancer	0.000351	0.000466	CcSEcCtD
Raltegravir—Arthralgia—Epirubicin—ovarian cancer	0.000349	0.000464	CcSEcCtD
Raltegravir—Chest pain—Epirubicin—ovarian cancer	0.000349	0.000464	CcSEcCtD
Raltegravir—Myalgia—Epirubicin—ovarian cancer	0.000349	0.000464	CcSEcCtD
Raltegravir—Agitation—Doxorubicin—ovarian cancer	0.000349	0.000464	CcSEcCtD
Raltegravir—Anxiety—Epirubicin—ovarian cancer	0.000348	0.000463	CcSEcCtD
Raltegravir—Nausea—Paclitaxel—ovarian cancer	0.000348	0.000463	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000347	0.000461	CcSEcCtD
Raltegravir—Discomfort—Epirubicin—ovarian cancer	0.000345	0.000459	CcSEcCtD
Raltegravir—Malaise—Doxorubicin—ovarian cancer	0.000342	0.000455	CcSEcCtD
Raltegravir—Dry mouth—Epirubicin—ovarian cancer	0.000342	0.000454	CcSEcCtD
Raltegravir—Vertigo—Doxorubicin—ovarian cancer	0.000341	0.000453	CcSEcCtD
Raltegravir—Diarrhoea—Docetaxel—ovarian cancer	0.00034	0.000452	CcSEcCtD
Raltegravir—Confusional state—Epirubicin—ovarian cancer	0.000338	0.000449	CcSEcCtD
Raltegravir—Palpitations—Doxorubicin—ovarian cancer	0.000335	0.000446	CcSEcCtD
Raltegravir—Infection—Epirubicin—ovarian cancer	0.000333	0.000442	CcSEcCtD
Raltegravir—Cough—Doxorubicin—ovarian cancer	0.000331	0.00044	CcSEcCtD
Raltegravir—Nervous system disorder—Epirubicin—ovarian cancer	0.000328	0.000437	CcSEcCtD
Raltegravir—Dizziness—Docetaxel—ovarian cancer	0.000328	0.000436	CcSEcCtD
Raltegravir—Thrombocytopenia—Epirubicin—ovarian cancer	0.000328	0.000436	CcSEcCtD
Raltegravir—Hypertension—Doxorubicin—ovarian cancer	0.000328	0.000436	CcSEcCtD
Raltegravir—Skin disorder—Epirubicin—ovarian cancer	0.000325	0.000432	CcSEcCtD
Raltegravir—Hyperhidrosis—Epirubicin—ovarian cancer	0.000324	0.00043	CcSEcCtD
Raltegravir—Chest pain—Doxorubicin—ovarian cancer	0.000323	0.00043	CcSEcCtD
Raltegravir—Myalgia—Doxorubicin—ovarian cancer	0.000323	0.00043	CcSEcCtD
Raltegravir—Arthralgia—Doxorubicin—ovarian cancer	0.000323	0.00043	CcSEcCtD
Raltegravir—Anxiety—Doxorubicin—ovarian cancer	0.000322	0.000428	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000321	0.000427	CcSEcCtD
Raltegravir—Discomfort—Doxorubicin—ovarian cancer	0.000319	0.000425	CcSEcCtD
Raltegravir—Dry mouth—Doxorubicin—ovarian cancer	0.000316	0.00042	CcSEcCtD
Raltegravir—Vomiting—Docetaxel—ovarian cancer	0.000316	0.00042	CcSEcCtD
Raltegravir—Rash—Docetaxel—ovarian cancer	0.000313	0.000416	CcSEcCtD
Raltegravir—Dermatitis—Docetaxel—ovarian cancer	0.000313	0.000416	CcSEcCtD
Raltegravir—Confusional state—Doxorubicin—ovarian cancer	0.000312	0.000415	CcSEcCtD
Raltegravir—Headache—Docetaxel—ovarian cancer	0.000311	0.000413	CcSEcCtD
Raltegravir—Infection—Doxorubicin—ovarian cancer	0.000308	0.000409	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000305	0.000406	CcSEcCtD
Raltegravir—Nervous system disorder—Doxorubicin—ovarian cancer	0.000304	0.000404	CcSEcCtD
Raltegravir—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000303	0.000403	CcSEcCtD
Raltegravir—Insomnia—Epirubicin—ovarian cancer	0.000303	0.000403	CcSEcCtD
Raltegravir—Skin disorder—Doxorubicin—ovarian cancer	0.000301	0.0004	CcSEcCtD
Raltegravir—Paraesthesia—Epirubicin—ovarian cancer	0.000301	0.0004	CcSEcCtD
Raltegravir—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000299	0.000398	CcSEcCtD
Raltegravir—Somnolence—Epirubicin—ovarian cancer	0.000298	0.000396	CcSEcCtD
Raltegravir—Nausea—Docetaxel—ovarian cancer	0.000295	0.000392	CcSEcCtD
Raltegravir—Dyspepsia—Epirubicin—ovarian cancer	0.000295	0.000392	CcSEcCtD
Raltegravir—Decreased appetite—Epirubicin—ovarian cancer	0.000291	0.000387	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000289	0.000384	CcSEcCtD
Raltegravir—Fatigue—Epirubicin—ovarian cancer	0.000289	0.000384	CcSEcCtD
Raltegravir—Constipation—Epirubicin—ovarian cancer	0.000286	0.000381	CcSEcCtD
Raltegravir—Pain—Epirubicin—ovarian cancer	0.000286	0.000381	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000282	0.000375	CcSEcCtD
Raltegravir—Insomnia—Doxorubicin—ovarian cancer	0.00028	0.000373	CcSEcCtD
Raltegravir—Paraesthesia—Doxorubicin—ovarian cancer	0.000278	0.00037	CcSEcCtD
Raltegravir—Feeling abnormal—Epirubicin—ovarian cancer	0.000276	0.000367	CcSEcCtD
Raltegravir—Somnolence—Doxorubicin—ovarian cancer	0.000275	0.000366	CcSEcCtD
Raltegravir—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000274	0.000364	CcSEcCtD
Raltegravir—Dyspepsia—Doxorubicin—ovarian cancer	0.000273	0.000363	CcSEcCtD
Raltegravir—Decreased appetite—Doxorubicin—ovarian cancer	0.000269	0.000358	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000267	0.000356	CcSEcCtD
Raltegravir—Fatigue—Doxorubicin—ovarian cancer	0.000267	0.000355	CcSEcCtD
Raltegravir—Urticaria—Epirubicin—ovarian cancer	0.000266	0.000354	CcSEcCtD
Raltegravir—Pain—Doxorubicin—ovarian cancer	0.000265	0.000352	CcSEcCtD
Raltegravir—Constipation—Doxorubicin—ovarian cancer	0.000265	0.000352	CcSEcCtD
Raltegravir—Abdominal pain—Epirubicin—ovarian cancer	0.000265	0.000352	CcSEcCtD
Raltegravir—Body temperature increased—Epirubicin—ovarian cancer	0.000265	0.000352	CcSEcCtD
Raltegravir—Feeling abnormal—Doxorubicin—ovarian cancer	0.000255	0.000339	CcSEcCtD
Raltegravir—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000253	0.000337	CcSEcCtD
Raltegravir—Hypersensitivity—Epirubicin—ovarian cancer	0.000247	0.000328	CcSEcCtD
Raltegravir—Urticaria—Doxorubicin—ovarian cancer	0.000246	0.000327	CcSEcCtD
Raltegravir—Abdominal pain—Doxorubicin—ovarian cancer	0.000245	0.000326	CcSEcCtD
Raltegravir—Body temperature increased—Doxorubicin—ovarian cancer	0.000245	0.000326	CcSEcCtD
Raltegravir—Asthenia—Epirubicin—ovarian cancer	0.00024	0.000319	CcSEcCtD
Raltegravir—Pruritus—Epirubicin—ovarian cancer	0.000237	0.000315	CcSEcCtD
Raltegravir—Diarrhoea—Epirubicin—ovarian cancer	0.000229	0.000305	CcSEcCtD
Raltegravir—Hypersensitivity—Doxorubicin—ovarian cancer	0.000228	0.000303	CcSEcCtD
Raltegravir—Asthenia—Doxorubicin—ovarian cancer	0.000222	0.000296	CcSEcCtD
Raltegravir—Dizziness—Epirubicin—ovarian cancer	0.000221	0.000294	CcSEcCtD
Raltegravir—Pruritus—Doxorubicin—ovarian cancer	0.000219	0.000291	CcSEcCtD
Raltegravir—Vomiting—Epirubicin—ovarian cancer	0.000213	0.000283	CcSEcCtD
Raltegravir—Diarrhoea—Doxorubicin—ovarian cancer	0.000212	0.000282	CcSEcCtD
Raltegravir—Rash—Epirubicin—ovarian cancer	0.000211	0.000281	CcSEcCtD
Raltegravir—Dermatitis—Epirubicin—ovarian cancer	0.000211	0.00028	CcSEcCtD
Raltegravir—Headache—Epirubicin—ovarian cancer	0.00021	0.000279	CcSEcCtD
Raltegravir—Dizziness—Doxorubicin—ovarian cancer	0.000205	0.000272	CcSEcCtD
Raltegravir—Nausea—Epirubicin—ovarian cancer	0.000199	0.000264	CcSEcCtD
Raltegravir—Vomiting—Doxorubicin—ovarian cancer	0.000197	0.000262	CcSEcCtD
Raltegravir—Rash—Doxorubicin—ovarian cancer	0.000195	0.00026	CcSEcCtD
Raltegravir—Dermatitis—Doxorubicin—ovarian cancer	0.000195	0.000259	CcSEcCtD
Raltegravir—Headache—Doxorubicin—ovarian cancer	0.000194	0.000258	CcSEcCtD
Raltegravir—Nausea—Doxorubicin—ovarian cancer	0.000184	0.000245	CcSEcCtD
